You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
From a Parkinson's disease expert: Rasagiline and the Future of Therapy
|
|---|---|
| Published in |
Molecular Neurodegeneration, July 2007
|
| DOI | 10.1186/1750-1326-2-13 |
| Pubmed ID | |
| Authors |
Shaheen E Lakhan |
| Abstract |
John Finberg is a professor of pharmacology at the Faculty of Medicine, Technion - Israel Institute of Technology, home of Israel's two Nobel laureates. He and his colleague Prof. Moussa Youdim were instrumental in the early clinical development of the anti-Parkinson drug rasagiline, which gained UK- and EU-marketing authorization in 2005 and US FDA approval in 2006. In our interview, Finberg reflects on his clinical research to develop rasagiline as a commercial drug and its proposed pharmacological mechanisms of action. Moreover, he elucidates the current state of anti-Parkinson drug discovery and offers direction for future research. |
Mendeley readers
The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 1 | 9% |
| United States | 1 | 9% |
| Unknown | 9 | 82% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 2 | 18% |
| Student > Doctoral Student | 1 | 9% |
| Student > Ph. D. Student | 1 | 9% |
| Professor | 1 | 9% |
| Researcher | 1 | 9% |
| Other | 1 | 9% |
| Unknown | 4 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 27% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 9% |
| Chemistry | 1 | 9% |
| Agricultural and Biological Sciences | 1 | 9% |
| Unknown | 5 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 April 2021.
All research outputs
#3,415,350
of 25,374,647 outputs
Outputs from Molecular Neurodegeneration
#522
of 977 outputs
Outputs of similar age
#8,257
of 78,344 outputs
Outputs of similar age from Molecular Neurodegeneration
#1
of 3 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 977 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.6. This one is in the 44th percentile – i.e., 44% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 78,344 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them